Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 November 10, 2026 Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update September 23, 2026 Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension September 16, 2026 Gossamer Bio Appoints Greg Ciongoli to Board of Directors September 11, 2026 Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split September 9, 2026 Gossamer Bio Announces 1-for-80 Reverse Stock Split September 4, 2026 Gossamer Bio to Present at Cantor Global Healthcare Conference August 21, 2026 Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval August 13, 2026 Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update July 27, 2026 Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update July 1, 2026 Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 November 10, 2026 Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update September 23, 2026 Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension September 16, 2026 Gossamer Bio Appoints Greg Ciongoli to Board of Directors September 11, 2026 Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split September 9, 2026 Gossamer Bio Announces 1-for-80 Reverse Stock Split September 4, 2026 Gossamer Bio to Present at Cantor Global Healthcare Conference August 21, 2026 Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval August 13, 2026 Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update July 27, 2026 Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update July 1, 2026 Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants